Full article view 2017-09-21T12:14:01+00:00
Back to News & Insights »

Kohler and Guennel Discuss Biomarker Drug Development & New FDA Data Requirements in Regulatory Focus

 

Precision for Medicine’s Jared Kohler and Tobias Guennel highlight the challenges for researchers pursuing biomarkers and specialty lab data that meet new FDA regulatory standards. Kohler and Guennel discuss how to leverage new technologies and subject matter expertise to improve efficiency and compliance.

To read the complete article, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.